Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data CAPRICOR THERAPEUTICS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
4
2.67
1.67
1.01
0.31
0.24
2.55
25.2
22.3
0
Research and development
16
10.8
12.1
5.14
8.46
13.6
21.8
36.4
50
84.5
General and administrative
4.93
4.76
4.93
3.6
5.54
7.61
10.4
12.8
14.9
23.7
Operating expenses
21
15.5
17
8.74
14
21.2
32.2
49.3
64.8
108
Operating income
-17
-12.9
-15.3
-7.73
-13.7
-20.9
-29.7
-24.1
-42.6
-108
Interest expense
0.34
0.4
0
0
3.05
Interest income
0.01
0.04
0.14
0.09
0.03
0.06
0.52
1.73
2.2
6.26
Other non-operating income
-1.83
15.3
0.14
0.09
0.03
0.92
0.68
1.79
2.1
3.1
Pre-tax income
-40.5
-105
Income tax
0
0
Net income
-18.8
2.43
-15.2
-7.64
-13.7
-20
-29
-22.3
-40.5
-105
EBITDA
-16.9
-12.7
-15.2
-7.56
-13.5
-20.7
-29.2
-23
-41.1
-106
EPS, basic
-1.01
0.10
-5.17
-2.06
-0.88
-0.87
-1.18
-0.83
-1.15
-2.26
EPS, diluted
-1.01
0.09
-0.52
-2.06
-0.88
-0.87
-1.18
-0.83
-1.15
-2.26
Shares, basic (weighted)
18.6
23.2
2.94
3.71
15.6
23.1
24.6
26.8
35.2
46.5
Shares, diluted (weighted)
18.6
26.8
2.94
3.71
15.6
23.1
24.6
26.8
35.2
46.5
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
3.2
6.14
4.26
3.9
32.7
34.9
9.6
14.7
11.3
288
Short-term investments
13
7.98
3
5.99
0
31.8
24.8
140
30.3
Other current assets
0.34
0.5
0.72
0.57
1.01
1.16
0.92
1
1.5
4.81
Total current assets
18.1
15.7
8.47
10.5
33.7
36.4
42.9
50.9
163
323
Property, plant and equipment
0.44
0.37
0.57
0.44
0.85
1.8
4.59
5.56
5.56
18.3
Lease right-of-use assets
0
2.82
2.35
2.05
1.31
13.5
Intangible assets
0.14
0.09
0.05
0.01
0
0
Total assets
18.7
16.3
9.25
11.1
34.6
41.3
50.1
58.7
170
356
Accounts payable
3.04
1.5
1.15
0.9
2.72
3.12
4.83
6.25
3.28
1.65
Accrued liabilities
4.91
15.6
Deferred revenue
1.37
0
0
18
24.3
12
12
Total current liabilities
4.9
1.67
1.26
0.9
2.97
4.13
23.6
31.3
21
35.8
Long-term debt
0
0.07
0
Lease liabilities
0
2.45
1.88
1.49
0.62
14.3
Total liabilities
22.8
5.05
4.63
4.27
6.42
9.96
38.3
36.1
25
50.2
Paid-in capital
50
62.7
71.3
81.2
116
139
149
182
344
610
Retained earnings
-54
-51.5
-66.7
-74.4
-88
-108
-137
-159
-200
-305
Other comprehensive income
0
0.01
0.01
-0
0
0
0.11
0.24
1.03
0.28
Shareholders' equity
-4
11.2
4.62
6.84
28.2
31.4
11.8
22.6
145
306
Total equity
-4
11.2
4.62
6.84
28.2
31.4
11.8
22.6
145
306
Total liabilities and equity
18.7
16.3
9.25
11.1
34.6
41.3
50.1
58.7
170
356
Shares outstanding
21.4
26.3
3.14
5.23
20.6
24.2
25.2
31.1
45.6
57.4
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-18.8
2.43
-15.2
-7.64
-13.7
-20
-29
-22.3
-40.5
-105
Depreciation and amortization
0.13
0.14
0.16
0.17
0.14
0.25
0.53
1.07
1.43
1.89
Stock-based compensation
1.96
1.71
1.73
0.7
1.95
2.97
4.46
7.39
9.77
17.2
Cash from operations
-14.5
-14.2
-13.9
-6.82
-10.1
-16.8
4.92
-25.6
-40
-69.8
Capital expenditures
-0.19
-0.03
-0.32
0
-0.55
-1.2
-2
-1.31
-1.17
-2.9
Purchases of investments
-18
-19
-18
-6
-6.13
0
-114
-97.4
-208
-151
Sales and maturities of investments
13
24
23
3
12.1
0
82.5
105
93.8
261
Cash from investing
-5.19
4.98
4.67
-3
5.44
-1.2
-35.1
5.11
-116
97.5
Debt issued
4.75
0.5
0
Stock issued
13.9
11.1
6.71
9.17
27.3
20.2
4.8
25.5
152
237
Share buybacks
0
-0
0
Cash from financing
18.6
11.6
6.85
9.18
33.4
20.2
4.87
25.6
153
249
Net change in cash
-2.36
2.33
-2.34
-0.65
28.8
2.22
-25.3
5.09
-3.41
277
Free cash flow
-14.6
-14.3
-14.2
-6.82
-10.6
-18
2.92
-26.9
-41.2
-72.7
Interest paid
0
0
0
0
0
0
0
0
0
0
Income taxes paid
0
0
0
0
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $8.36 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-52.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-35.1%
Net income / average total assets.
Return on invested capital (ROIC)
-47.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-100.0%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
110.2%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
196.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
61.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
108.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
92.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
59.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
32.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
23.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
24.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
7.35x
Current assets / current liabilities.
Quick ratio
7.22x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
7.22x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.98
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.80
Cash from operations / diluted weighted shares.
Book value per share
$4.24
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.97x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.97x
Market cap / tangible book value, when positive.
FCF yield
-23.6%
Free cash flow / market cap.
Earnings yield
-26.6%
Net income / market cap (the inverse of P/E).
What was CAPRICOR THERAPEUTICS, INC.'s revenue in fiscal 2025?
CAPRICOR THERAPEUTICS, INC. reported revenue of $0.0 for fiscal 2025, 100% lower than the year before.
Was CAPRICOR THERAPEUTICS, INC. profitable in fiscal 2025?
No. It reported a net loss of $105.0M.
How much free cash flow did CAPRICOR THERAPEUTICS, INC. generate in fiscal 2025?
Cash from operations of $69.8M minus capital expenditures of $2.9M left free cash flow of -$72.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.